HJB And Ansun Biopharma Enters Into A Biologics Partnership.
HJB, a dedicated biologics contract development and manufacturing organization (CDMO), has recently entered into a partnership for CMC development and manufacturing with Ansun Biopharma on its therapeutic biologics pipeline.
Ansun Biopharma will be able to leverage HJB’s expertise and capacities from cell line development, process and assay development to GMP manufacturing, IND-enabling full-service package, and clinical and commercial supply in the global territory for the next three years, according to the agreement.
Ansun Biopharma’s Chief Technology Officer, George Wang says that they are very excited about this new partnership with HJB as they continue the expansion of its product pipeline.
HJB’s General Manager, Jerry Yang also said that they are also excited to be picked as the CMC development and manufacturing partner of Ansun to support expedited and high-quality packages of their innovative biologics programs, adding that they will continue creating value to all its business partners.
A team of researchers develops double-barreled syringe for subcutaneous biologics injections
Researchers at the Massachusetts Institute of Technology (MIT) have developed a device that could potentially dethrone infusions as the typical biologics delivery route: a double-barreled, lubricated syringe that makes it possible to inject high-concentration biologic drugs or even vaccines.
The research team, led by professor Varanasi, designed the syringe to combine the injectable drug with a thin layer of lubricant when the device’s plunger is pressed down. The syringe requires one-seventh of the force needed to manually inject biologics, which typically must be diluted and administered via infusion.
The team hopes the device could tee up easier dosing for the more than 100 drugs currently considered too viscous for subcutaneous injection.
Catalent Biologics Adds A $50 Million Third High-Speed Vial Line At Its Indiana Site.
Catalent recently announced that it is investing a sum of $50 million to install an additional high-speed vial filling line at its facility in Indiana, United States.
The new line is expected to be operational by April 2021 and will add capacity to support the growing pipeline of clinical programs and commercial launches at the site. It will provide sufficient capacity to produce up to 80 million vials annually under barrier isolator technology and a peristaltic pump filling mechanism, consistent with current good manufacturing practice (CGMP) regulations.
With its considerable experience in facility and capacity expansions, the Bloomington site has been able to accelerate the overall project from a typical 18-month timeframe to approximately 10 months in total, including construction, procurement, installation, and CGMP qualification of the new line.
This new addition is the third major investment that Catalent made over the last two years at its Indiana site.